Literature DB >> 15670081

Serum oxidant/antioxidant balance in exfoliation syndrome.

Ayça Yimaz1, Ufuk Adigüzel, Lülüfer Tamer, Ozlem Yildirim, Ozay Oz, Halil Vatansever, Bahadir Ercan, Ula S Değirmenci, Uğur Atik.   

Abstract

BACKGROUND: To evaluate the relationship between the serum oxidant-antioxidant balance and the presence of exfoliation syndrome (XFS) in a prospective study.
METHODS: The study group comprised 27 cases of XFS. Serum concentrations of myeloperoxidase, malondialdehyde, vitamins A, C and E, catalase and total antioxidant were measured and compared with an independent group by t-test.
RESULTS: Serum myeloperoxidase, vitamins A and E, catalase and total antioxidant parameters were not statistically different among the groups (P >0.05). Serum vitamin C concentrations were significantly lower and malondialdehyde concentrations were significantly higher in cases of XFS when compared with the control group (P=0.008 and P=0.002, respectively).
CONCLUSION: An altered oxidant-antioxidant balance may play a role in the pathogenesis of XFS.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15670081     DOI: 10.1111/j.1442-9071.2005.00944.x

Source DB:  PubMed          Journal:  Clin Exp Ophthalmol        ISSN: 1442-6404            Impact factor:   4.207


  13 in total

1.  Disturbed oxidant/antioxidant balance in aqueous humour of patients with exfoliation syndrome.

Authors:  Emrullah Beyazyıldız; Ali Bülent Cankaya; Ozlem Beyazyıldız; Esra Ergan; Hüseyin Tuğrul Celik; Pelin Yılmazbaş; Faruk Oztürk
Journal:  Jpn J Ophthalmol       Date:  2014-05-27       Impact factor: 2.447

2.  Serum prolidase activity and oxidative stress in patients with pseudoexfoliation syndrome.

Authors:  Mehmet Tetikoğlu; Haci Murat Sağdik; Serdar Aktas; Fatma Uçar; Fatih Özcura
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-04-15       Impact factor: 3.117

3.  Directed therapy for exfoliation syndrome.

Authors:  Allison Angelilli; Robert Ritch
Journal:  Open Ophthalmol J       Date:  2009-09-17

4.  Directed Therapy: An Approach to the Improved Treatment of Exfoliation syndrome.

Authors:  Allison Angelilli; Robert Ritch
Journal:  Middle East Afr J Ophthalmol       Date:  2009-01

5.  Variability of serum oxidative stress biomarkers relative to biochemical data and clinical parameters of glaucoma patients.

Authors:  Kaya N Engin; Bülent Yemişci; Ulviye Yiğit; Ahmet Ağaçhan; Cihan Coşkun
Journal:  Mol Vis       Date:  2010-07-09       Impact factor: 2.367

6.  Prooxidant-antioxidant balance, peroxide and catalase activity in the aqueous humour and serum of patients with exfoliation syndrome or exfoliative glaucoma.

Authors:  George G Koliakos; Christina D Befani; Dimitrios Mikropoulos; Nikolaos G Ziakas; Anastasios G P Konstas
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-07-08       Impact factor: 3.117

7.  Total oxidative stress, paraoxonase and arylesterase levels at patients with pseudoexfoliation syndrome and pseudoexfoliative glaucoma.

Authors:  Feyza Dursun; Ayse Vural Ozec; Huseyin Aydin; Aysen Topalkara; Ayhan Dursun; Mustafa Ilker Toker; Haydar Erdogan; Mustafa Kemal Arici
Journal:  Int J Ophthalmol       Date:  2015-10-18       Impact factor: 1.779

8.  Quantitative analysis of SOD2, ALDH1A1 and MGST1 messenger ribonucleic acid in anterior lens epithelium of patients with pseudoexfoliation syndrome.

Authors:  Barbara Strzalka-Mrozik; Lilianna Prudlo; Malgorzata W Kimsa; Magdalena C Kimsa; Malgorzata Kapral; Malgorzata Nita; Urszula Mazurek
Journal:  Mol Vis       Date:  2013-06-12       Impact factor: 2.367

9.  Clinical and Optical Coherence Tomography Features in Unilateral versus Bilateral Pseudoexfoliation Syndrome.

Authors:  Aparna Rao
Journal:  J Ophthalmic Vis Res       Date:  2012-07

10.  Paraoxonase 1 (PON1) promoter (-107T/C) and coding region (192Q/R and 55L/M) genetic variations in pseudoexfoliation syndrome and pseudoexfoliative glaucoma risk.

Authors:  Birsen Can Demirdöğen; Canan Koçan Akçin; Ezgi Göksoy; Gizem Yakar; Tuğçe Öztepe; Sinem Demirkaya-Budak; Sinan Oflaz
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-07-10       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.